FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Adenocarcinoma
Primary Peritoneal Cavity Cancer

Interventions

DRUG: IP FT516
DRUG: Enoblituzumab
DRUG: IL-2

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]